Therapeutic Index

Switching to ALTROL CR showed no significant survival benefit over tamoxifen therapy.

ALTROL CR^® (exemestane tablets) is a prescription medicine for the adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer. Treatment with ALTROL CR should begin after 2 to 3 years of tamoxifen, at which time tamoxifen should be discontinued. Treatment with ALTROL CR should continue for 2 to 3 years (until the completion of a total of 5 years of adjuvant treatment with tamoxifen and ALTROL CR).

Sorting through all the information on different breast cancer treatments can be a challenge. But if you're looking for information on ALTROL CR^® (exemestane tablets), you've come to the right place. With a few clicks of a mouse, you'll learn about ALTROL CR. Together, you and your doctor can make an informed decision about your treatment.

ALTROL CR Tablets for oral administration contain 25 mg of exemestane, an irreversible, steroidal aromatase inactivator. Exemestane is chemically described as 6-methylenandrosta- 1,4-diene-3,17-dione. Its molecular formula is C20H24O2 and its structural formula is as follows:

The active ingredient is a white to slightly yellow crystalline powder with a molecular weight of 296.41. Exemestane is freely soluble in N, N-dimethylformamide, soluble in methanol, and practically insoluble in water.
Each ALTROL CR Tablet contains the following inactive ingredients: mannitol,
crospovidone, polysorbate 80, hypromellose, colloidal silicon dioxide, microcrystalline cellulose, sodium starch glycolate, magnesium stearate, simethicone, polyethylene glycol 6000, sucrose, magnesium carbonate, titanium dioxide, methylparaben, and polyvinyl alcohol.

If your doctor prescribes ALTROL CR, you would stop taking tamoxifen and start taking ALTROL CR for 2 to 3 years for a combined total of 5 years of adjuvant (AD-joo-vant) treatment. Adjuvant treatment for breast cancer is a treatment given after surgery, radiation, or chemotherapy.

ALTROL CR^® (exemestane tablets) is a prescription medicine for the adjuvant treatment of postmenopausal women with estrogen-receptor positive early breast cancer. Treatment with ALTROL CR should begin after 2 to 3 years of tamoxifen, at which time tamoxifen should be discontinued. Treatment with ALTROL CR should continue for 2 to 3 years (until the completion of a total of 5 years of adjuvant treatment with tamoxifen and ALTROL CR)
Each tablet contains:

Composition:
Exemestane Tablets..........................25mg
 

Hormonal therapy and breast cancer.

Most breast cancer cells may need the hormone estrogen to grow. That's why they may be called estrogen-dependent or estrogen-receptor positive (ER+) cancers.

Both tamoxifen and ALTROL CR^® (exemestane tablets) are hormonal therapies, meaning they interfere with the normal function of estrogen. But there is a difference in how they work.

Tamoxifen blocks estrogen from attaching itself to breast cancer cells. ALTROL CR helps stop the production of estrogen in postmenopausal women. ALTROL CR can lower the amount of estrogen in postmenopausal women by 98%. Less estrogen may mean less risk of estrogen-dependent tumor growth. It is important to note that no significant survival benefit was seen over tamoxifen therapy.

See how ALTROL CR and tamoxifen work.

It's smart to know what others have experienced with ALTROL CR.

Medicines can have benefits and side effects. It's good for you and your doctor to think about both when deciding on a treatment plan. Below are some of the most common side effects women had during the ALTROL CR^® (exemestane tablets) IES study. Side effects were usually mild to moderate. Below you can find ways to help manage some of the common side effects. Always report new or different side effects to your doctor right away to be sure they are not a sign of something more serious.

Note: ONLY FOR EXPORT

PACKAGING INFORMATION :
15 Tablets Per Blister